Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer

BACKGROUND: Clinical benefit of cellular immunotherapy has been shown in patients with castration-resistant prostate cancer (CRPC). We investigated the immunological response and clinical outcome of vaccination with blood-derived CD1c(+) myeloid dendritic cells (mDCs; cDC2) and plasmacytoid DCs (pDC...

Descripción completa

Detalles Bibliográficos
Autores principales: Westdorp, Harm, Creemers, Jeroen H. A., van Oort, Inge M., Schreibelt, Gerty, Gorris, Mark A. J., Mehra, Niven, Simons, Michiel, de Goede, Anna L., van Rossum, Michelle M., Croockewit, Alexandra J., Figdor, Carl G., Witjes, J. Alfred, Aarntzen, Erik H. J. G., Mus, Roel D. M., Brüning, Mareke, Petry, Katja, Gotthardt, Martin, Barentsz, Jelle O., de Vries, I. Jolanda M., Gerritsen, Winald R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854814/
https://www.ncbi.nlm.nih.gov/pubmed/31727154
http://dx.doi.org/10.1186/s40425-019-0787-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854814/
https://www.ncbi.nlm.nih.gov/pubmed/31727154
http://dx.doi.org/10.1186/s40425-019-0787-6

Ejemplares similares